HC Wainwright Issues Pessimistic Forecast for VRDN Earnings

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Equities researchers at HC Wainwright lowered their Q3 2026 earnings per share estimates for Viridian Therapeutics in a research report issued on Thursday, August 6th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($1.13) per share for the quarter, down from their prior estimate of ($1.09). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.02) per share. HC Wainwright also issued estimates for Viridian Therapeutics’ Q4 2026 earnings at ($1.21) EPS, FY2027 earnings at ($3.35) EPS, FY2028 earnings at ($2.87) EPS, FY2029 earnings at ($1.49) EPS and FY2030 earnings at $0.40 EPS.

Several other brokerages have also issued reports on VRDN. The Goldman Sachs Group reissued a “buy” rating and set a $39.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, June 30th. Evercore set a $26.00 price target on shares of Viridian Therapeutics in a research note on Friday, May 15th. Weiss Ratings lowered shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Stifel Nicolaus set a $39.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, May 13th. Finally, Wedbush raised their target price on Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. Thirteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.93.

Viridian Therapeutics Stock Performance

NASDAQ:VRDN opened at $23.06 on Monday. The company has a fifty day moving average of $18.51 and a 200-day moving average of $21.52. The firm has a market capitalization of $2.61 billion, a P/E ratio of -6.84 and a beta of 0.91. The company has a quick ratio of 15.15, a current ratio of 15.15 and a debt-to-equity ratio of 0.10. Viridian Therapeutics has a twelve month low of $13.18 and a twelve month high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.02). The business had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.06 million. Viridian Therapeutics had a negative return on equity of 76.65% and a negative net margin of 505.86%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Perceptive Advisors LLC lifted its stake in Viridian Therapeutics by 108.1% during the 4th quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company’s stock valued at $94,689,000 after acquiring an additional 1,580,303 shares in the last quarter. Morgan Stanley grew its stake in shares of Viridian Therapeutics by 805.6% in the 4th quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock worth $54,094,000 after acquiring an additional 1,546,284 shares in the last quarter. Avoro Capital Advisors LLC purchased a new stake in shares of Viridian Therapeutics in the fourth quarter valued at about $46,680,000. Vanguard Group Inc. raised its holdings in shares of Viridian Therapeutics by 29.6% in the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock valued at $174,650,000 after purchasing an additional 1,280,161 shares during the last quarter. Finally, Commodore Capital LP lifted its position in shares of Viridian Therapeutics by 35.4% during the second quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock valued at $68,152,000 after purchasing an additional 1,275,000 shares in the last quarter.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.